Destiny Pharma – Landmark XF-73 Phase 2 data published in journal
Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology
Demonstrates significant reduction of nasal S. aureus in preoperative cardiac surgery patients
Brighton, United Kingdom – 24 March 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, is pleased to announce the publication of landmark XF-73 clinical data in the leading US peer reviewed journal “Infection Control & Hospital Epidemiology”.
The paper was published by Dr. Julie Mangino (Professor Emeritus, Division of Infectious Diseases, at The Ohio State University, US) who is the lead author and a member of the Data Safety Monitoring Committee for the clinical trial.
The paper is entitled, ‘Exeporfinium Chloride (XF-73) Nasal Gel Dosed over 24 Hours Prior to Surgery Significantly Reduced Staphylococcus aureus Nasal Carriage in Cardiac Surgery Patients: Safety and Efficacy Results from a Randomized Placebo-Controlled Phase 2 Study’. https://doi.org/10.1017/ice.2023.17